• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A biotech company developing and commercializing vaccines for infectious diseases with major unmet needs

VAL_Report_2018_Teaser_Website_Home_800x400_190320.jpg

Download 2018 Valneva Annual Business Report


May 22, 2019
Valneva Reports Further Positive Results for Its Chikungunya Vaccine Candidate
Read more

— Stock information

@valnevase




-
— January 31, 2019
Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate

Read more
— Vienna Stock Exchange Delisting /
Delisting von der Wiener Börse

Shareholder information
Informationen für Aktionäre


— Financial Calendar

Shareholders' meeting

June 27, 2019, Paris
Read more

See all dates

AKTUELLES

News in German


 
VALNEVA
LIBRARY


Images, presentations and videos

JAPANESE
ENCEPHALITIS
AND
CHOLERA



learn more
play video Company Video

– Upcoming conferences


Bio International Convention
June 3-6, 2019, Philadelphia

Raymond James Sciences & Medtech Conference
 
June 18-19, 2019, New York

France Biotech Health Tech Investor Day
June 24-25, 2019, Paris


Please update your browser...